Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals reported a significant increase in DAYBUE™ net sales for Q2 2025, reaching US$96.1 million, a 14% rise from the previous year. This growth is attributed to an increase in unique patient shipments and an expanded sales force by Acadia Pharmaceuticals, Neuren’s partner. The company anticipates continued growth, with substantial potential in the US market as many diagnosed Rett syndrome patients have yet to try DAYBUE. Additionally, Acadia is preparing for European market entry with named patient supply programs already initiated.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$29.75 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development of therapies for neurological disorders. The company’s primary product is DAYBUE™ (trofinetide), which targets Rett syndrome, a rare neurological disorder. Neuren collaborates with Acadia Pharmaceuticals to market DAYBUE in the United States and is expanding its reach in Europe and other global markets.
Average Trading Volume: 534,603
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.13B
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.